Guava appoints its chairman, John Walker, as interim chief executive officer following the resignation of previous president Rajen Dalal
Guava Technologies has announced the appointment of its chairman, John Walker, as interim chief executive officer.
He replaces Rajen Dalal, Guava's previous president and CEO, who has resigned from the company.
Walker's career spans over 30 years of management experience within the health care and biotechnology industry.
In addition to his work with Guava Technologies, he serves as an investment advisor to MDS Capital, a Guava investor, and as vice chairman, Renovis, a biotechnology company.
He also serves on the board of directors of publicly held biotechnology companies Discovery Partners International, and Geron.
He is additionally a member of the board of directors at privately held biotechnology company KAI Pharmaceuticals, where he previously served as interim CEO.
He has also previously served as chairman and CEO of Bayhill Therapeutics, chairman and interim CEO of Centaur Pharmaceuticals, was past chairman and CEO of Axys Pharmaceuticals and its predecessor company Arris Pharmaceutical, and has been chairman of both Microcide and Signal Pharmaceuticals.
Guava Technologies is a venture-backed biotechnology company based in Hayward, California.
Guava's product offerings combine instrument platforms with a variety of assays and software modules to provide complete, integrated systems for easy-to-use on-demand cellular analysis.
